A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology

Trial Profile

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Flutafuranol F 18 (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacodynamics; Registrational
  • Sponsors Navidea Biopharmaceuticals
  • Most Recent Events

    • 25 Jul 2017 Planned End Date changed from 1 Dec 2017 to 1 Sep 2018.
    • 25 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
    • 24 Jul 2015 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top